Investigational Drug Information for OTO-104
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug OTO-104?
OTO-104 is an investigational drug.
There have been 27 clinical trials for OTO-104.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 13th 2021.
The most common disease conditions in clinical trials are Meniere Disease, Otitis, and Otitis Media. The leading clinical trial sponsors are Otonomy, Inc., University of St Andrews, and Stellah Mpagama.
There are eight hundred and thirty-two US patents protecting this investigational drug and forty-two international patents.
Summary for OTO-104
| US Patents | 832 |
| International Patents | 42,864 |
| US Patent Applications | 4,537 |
| WIPO Patent Applications | 2,798 |
| Japanese Patent Applications | 14 |
| Clinical Trial Progress | Phase 3 (2021-01-13) |
| Vendors | 80 |
Recent Clinical Trials for OTO-104
| Title | Sponsor | Phase |
|---|---|---|
| A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis | Radboud University Medical Center | Phase 3 |
| A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis | University of St Andrews | Phase 3 |
| A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis | Stellah Mpagama | Phase 3 |
Clinical Trial Summary for OTO-104
Top disease conditions for OTO-104
Top clinical trial sponsors for OTO-104
US Patents for OTO-104
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| OTO-104 | See Plans and Pricing | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | See Plans and Pricing |
| OTO-104 | See Plans and Pricing | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | See Plans and Pricing |
| OTO-104 | See Plans and Pricing | Salts of an epidermal growth factor receptor kinase inhibitor | Celgene CAR LLC (Pembroke, BM) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for OTO-104
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| OTO-104 | Australia | AU2011326871 | 2030-11-08 | See Plans and Pricing |
| OTO-104 | Brazil | BR112013010157 | 2030-11-08 | See Plans and Pricing |
| OTO-104 | Canada | CA2815749 | 2030-11-08 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
